

## Supplementary Data Information

**Title:** Supplementary Data 1.

**Description:** Summary of the study cohorts.

**Title:** Supplementary Data 2.

**Description:** Credible sets of the 25 fine-mapped loci.

**Title:** Supplementary Data 3.

**Description:** Expression Quantitative Trait loci (eQTLs) of the SNPs from credible sets.

**Title:** Supplementary Data 4.

**Description:** Exonic non-synonymous variants from credible sets or exonic non-synonymous variants in high to moderate LD ( $r^2 \geq 0.8$ ,  $r^2 \geq 0.6$ , respectively) with SNPs from credible sets.

**Title:** Supplementary Data 5.

**Description:** SNPs from credible sets showing pleiotropic effect in other diseases.

**Title:** Supplementary Data 6.

**Description:** Promoter capture Hi-C target genes in immune cell types and eQTL validation for the 27 systemic sclerosis association signals.

**Title:** Supplementary Data 7.

**Description:** Gene prioritization by means of DEPICT.

**Title:** Supplementary Data 8.

**Description:** Significant enrichments for epigenetic marks in 59 cell/tissue types analyzed.

**Title:** Supplementary Data 9.

**Description:** Non-HLA loci Associated with SSc clinical subphenotypes.

**Title:** Supplementary Data 10.

**Description:** Non-HLA loci associated with SSc autoantibody status.

**Title:** Supplementary Data 11.

**Description:** Gene-products nominated in the meta-analysis for systemic sclerosis and their related drugs.

Supplementary Data 12. Summary of the functional annotation data integrated in the statistical fine-mapping.

Supplementary Data 13. Reference epigenomes from the Roadmap Epigenomics Consortium and the Encyclopedia of DNA Elements (ENCODE) projects.